UNICREDIT BANK/CALL/BIOGEN IDEC/400/0.1/14.01.26 | Real-time BOERSE MUENCHEN 09:41:30 2024-05-17 EDT | ||
| 1.17 EUR | -1.68% |
|
| Current month | +72.46% | ||
| 1 month | +142.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 1.17 | -1.68% |
| 24-05-16 | 1.19 | -5.56% |
| 24-05-15 | 1.26 | +17.76% |
| 24-05-14 | 1.07 | +5.94% |
| 24-05-13 | 1.01 | +9.78% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 09:41 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD28PH |
| ISIN | DE000HD28PH8 |
| Date issued | 2024-01-29 |
| Strike | 400 $ |
| Maturity | 2026-01-14 (607 Days) |
| Parity | 10 : 1 |
| Emission price | 1.67 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.65 € |
|---|---|
| Lowest since issue | 0.44 € |
| Spread | 0.02 € |
| Spread % | 1.71% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230
USD
Average target price
285.9
USD
Spread / Average Target
+24.29%
- Stock Market
- Warrants
- Warrant
